Rethinking the Pharma/Biopharma Supply Chain to Maximize Resilience

Pharma’s Almanac is excited to host this roundtable webinar about increasing supply chain resilience in partnership with our sponsor Samsung Biologics.

In the dynamic landscape of the (bio)pharmaceutical industry, the resilience of the supply chain has emerged as a critical factor in ensuring uninterrupted production and delivery of life-saving therapies. How can we build on recent lessons learn and establish a more robust supply chain?

In a lively conversation, "Rethinking the Pharma/Biopharma Supply Chain to Maximize Resilience," the panel will offer a range of perspectives on the supply chain challenges across sectors and continents and solutions that will maximize resilience.

Our panel includes:
Yongkwan Ma, Associate Director of Chemical, Media, and Resin Procurement at Samsung Biologics,
Tim Tyson, Chairman and CEO at TriRx Pharmaceutical Services,
Jesse McCool, Ph.D., CEO at Wheeler Bio, and
Russell Harris, Managing Director at K-CRAB Consulting.

In this free webinar, you will learn:

  • The key factors complicating the supply chain
  • Lessons learned from the disruption of the COVID-19 pandemic
  • Strategies and technologies that have proven effective in mitigating disruptions and ensuring a continuous supply
  • Roles for role does digitalization, data analytics, and real-time monitoring
  • Trends and developments that will shape the future of supply chain management
  • And more. 

Gain valuable insights into the pharma/biopharma supply chain. 

Yongkwan Ma

Yongkwan Ma is an associate director of Chemical, Media, and Resin Procurement at Samsung Biologics. He has 12 years of experience in Supply Management at Samsung, expanding his expertise into CAPEX/Raw Material Purchase, Supply Planning, Supplier Relationship Management (SRM), and Project Procurement Management (PPM). His commitment to end-to-end supply chain principles is the cornerstone of his leadership philosophy, enabling well-timed access to healthcare treatment for more patients.